Treatment strategies for oesophageal cancer - time-trends and long term outcome data from a large tertiary referral centre

Radiation Oncology

Claus Belka¹  Dieter Hölzel²  Michael Schmidt²  Franz Zehentmayr¹  Maria C Wolf¹ 

[1] Department of Radiation Oncology, LMU University Hospital Munich, Marchioninistraße 15, 81377 München, Germany;Institute for medical Information processing, Biometry and Epidemiology, LMU University Hospital Munich, Marchioninistraße 15, 81377 München, Germany

关键词: Squamous cell carcinoma;    Adenocarcinoma;    Radio-chemotherapy;    Oesophageal cancer;   

Others  :  1160856
DOI  :  10.1186/1748-717X-7-60

 received in 2011-11-15, accepted in 2012-04-15,  发布年份 2012

【 摘 要 】

Background and objectives

Treatment options for oesophageal cancer have changed considerably over the last decades with the introduction of multimodal treatment concepts dominating the progress in the field. However, it remains unclear in how far the documented scientific progress influenced and changed the daily routine practice. Since most patients with oesophageal cancer generally suffer from reduced overall health conditions it is uncertain how high the proportion of aggressive treatments is and whether outcomes are improved substantially. In order to gain insight into this we performed a retrospective analysis of patients treated at a larger tertiary referral centre over time course of 25 years.

Patients and methods

Data of all patients diagnosed with squamous cell carcinoma (SCC) and adenocarcinoma (AC) of the oesophagus, treated between 1983 and 2007 in the department of radiation oncology of the LMU, were obtained. The primary endpoint of the data collection was overall survival (calculated from the date of diagnosis until death or last follow up). Changes in basic clinical characteristics, treatment approach and the effect on survival were analysed after dividing the cohort into five subsequent time periods (I-V) with 5 years each. In a second analysis any pattern of change regarding the use of radio(chemo)therapy (R(C)T) with and without surgery was determined.

Results

In total, 503 patients with SCC (78.5%) and AC (18.9%) of the oesophagus were identified. The average age was 60 years (range 35-91 years). 56.5% of the patients were diagnose with advanced UICC stages III-IV. R(C)T was applied to 353 (70.2%) patients; R(C)T+ surgery was performed in 134 (26.6%) patients, 63.8% of all received chemotherapy (platinum-based 5.8%, 5-fluorouracil (5-FU)12.1%, 42.3% 5-FU and mitomycin C (MMC)). The median follow-up period was 4.3 years. The median overall survival was 21.4 months. Over the time, patients were older, the formal tumour stage was more advanced, the incidence of AC was higher and the intensified treatment had a higher prevalence. However there was only a trend for an improved OS over the years with no difference between RCT with or without surgery (p = 0.09). The use of radiation doses over 54 Gy and the addition of chemotherapy (p = 0.002) were associated with improved OS.

Conclusion

Although more complex treatment protocols were introduced into clinical routine, only a minor progress in OS rates was detectable. Main predictors of outcome in this cohort was the addition of chemotherapy. The addition of surgery to radio-chemotherapy may only be of value for very limited patient groups.

【 授权许可】

   
2012 Wolf et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figures 4.

【 参考文献 】

• [1]Berger B, Belka C: Evidence-based radiation oncology: oesophagus. Radiother Oncol 2009, 92(2):276-290.
• [2]Wolf MC, Stahl M, Krause BJ, Bonavina L, Bruns C, Belka C, Zehentmayr F: Curative treatment of oesophageal carcinoma: current options and future developments. Radiat Oncol 2011, 6:55. BioMed Central Full Text
• [3]Chiu PW, Chan AC, Leung SF, Leong HT, Kwong KH, Li MK, Au-Yeung AC, Chung SC, Ng EK: Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg 2005, 9(6):794-802.
• [4]Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, et al.: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007, 25(10):1160-1168.
• [5]Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, et al.: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997, 337(3):161-167.
• [6]Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, et al.: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005, 6(9):659-668.
• [7]Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, et al.: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. Jama 1999, 281(17):1623-1627.
• [8]Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992, 326(24):1593-1598.
• [9]Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, et al.: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005, 23(10):2310-2317.
• [10]Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Konigsrainer A, et al.: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009, 27(6):851-856.
• [11]Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996, 335(7):462-467.
• [12]Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007, 8(3):226-234.
• [13]Wolf M, Zehentmayr F, Niyazi M, Ganswindt U, Haimerl W, Schmidt M, Holzel D, Belka C, et al.: Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. Strahlentherapie und Onkologie. Organ der Deutschen Rontgengesellschaft 2010, 186(7):374-381.
• [14]Wong R, Malthaner R: Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006, (1):CD002092.
• [15]Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. The lancet oncology 2011, 12(7):681-692.
• [16]Polednak AP: Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. International journal of cancer Journal international du cancer 2003, 105(1):98-100.
• [17]Allum WH, Griffin SM, Watson A, Colin-Jones D: Guidelines for the management of oesophageal and gastric cancer. Gut 2002, 50(Suppl 5):v1-23.
• [18]Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, et al.: Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008, 49(3):480-508.
• [19]van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD: Staging investigations for oesophageal cancer: a meta-analysis. British journal of cancer 2008, 98(3):547-557.
• [20]Wallace MB, Nietert PJ, Earle C, Krasna MJ, Hawes RH, Hoffman BJ, Reed CE: An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. The Annals of thoracic surgery 2002, 74(4):1026-1032.
• [21]Devesa SS, Blot WJ, Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998, 83(10):2049-2053.
• [22]DeMeester SR: Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol 2006, 13(1):12-30.
• [23]Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005, 97(2):142-146.
• [24]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96.
• [25]Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med 2003, 349(23):2241-2252.
• [26]Dolan K, Sutton R, Walker SJ, Morris AI, Campbell F, Williams EM: New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology. Br J Cancer 1999, 80(5-6):834-842.
• [27]Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH: Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001, 92(3):549-555.
• [28]Chang DT, Chapman C, Shen J, Su Z, Koong AC: Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysis. American journal of clinical oncology 2009, 32(4):405-410.
• [29]Fukuzawa K, Noguchi Y, Yoshikawa T, Saito A, Doi C, Makino T, Takanashi Y, Ito T, Tsuburaya A: High incidence of synchronous cancer of the oral cavity and the upper gastrointestinal tract. Cancer Lett 1999, 144(2):145-151.
• [30]Welz S, Schmid A, Hehr T, Schulze K, Feldmann HJ, Budach W, Bamberg M, Belka C: Treatment-outcome for synchronous head-and-neck and oesophageal squamous cell carcinoma. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 2005, 77(3):267-270.
• [31]Mariette C, Piessen G, Triboulet JP: Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007, 8(6):545-553.
• [32]Coia LR, Engstrom PF, Paul AR, Stafford PM, Hanks GE: Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys 1991, 20(1):29-36.
• [33]Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L, Emami B: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer. an intergroup study. J Clin Oncol 1997, 15(1):277-284.
• [34]Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2002, 20(5):1167-1174.
• [35]Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R: Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol 2006, 78(3):236-244.
• [36]Enestvedt CK, Perry KA, Kim C, McConnell PW, Diggs BS, Vernon A, O'Rourke RW, Luketich JD, Hunter JG, Jobe BA: Trends in the management of esophageal carcinoma based on provider volume: treatment practices of 618 esophageal surgeons. Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus/ISDE 2010, 23(2):136-144.
• [37]Schwer AL, Ballonoff A, McCammon R, Rusthoven K, D'Agostino RB Jr, Schefter TE: Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study. International journal of radiation oncology, biology, physics 2009, 73(2):449-455.
• [38]Cronin-Fenton DP, Sharp L, Carsin AE, Comber H: Patterns of care and effects on mortality for cancers of the oesophagus and gastric cardia: a population-based study. European journal of cancer 2007, 43(3):565-575.
• [39]Brown LM, Hoover R, Silverman D, Baris D, Hayes R, Swanson GM, Schoenberg J, Greenberg R, Liff J, Schwartz A, et al.: Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidemiol 2001, 153(2):114-122.
• [40]Brenner B, Ilson DH, Minsky BD: Treatment of localized esophageal cancer. Seminars in oncology 2004, 31(4):554-565.
• [41]Koshy M, Esiashvilli N, Landry JC, Thomas CR Jr, Matthews RH: Multiple management modalities in esophageal cancer: combined modality management approaches. Oncologist 2004, 9(2):147-159.
• [42]Palma P, Conde-Muino R, Rodriguez-Fernandez A, Segura-Jimenez I, Sanchez-Sanchez R, Martin-Cano J, Gomez-Rio M, Ferron JA, Llamas-Elvira JM: The value of metabolic imaging to predict tumour response after chemoradiation in locally advanced rectal cancer. Radiat Oncol 2010, 5:119. BioMed Central Full Text
• [43]Kanakamedala MR, Packianathan S, Vijayakumar S: Lack of Cetuximab induced skin toxicity in a previously irradiated field: case report and review of the literature. Radiat Oncol 2010, 5:38.
• [44]Du L, Zhou LJ, Pan XJ, Wang YX, Xu QZ, Yang ZH, Wang Y, Liu XD, Zhu MX, Zhou PK: Radiosensitization and growth inhibition of cancer cells mediated by an scFv antibody gene against DNA-PKcs in vitro and in vivo. Radiat Oncol 2010, 5:70. BioMed Central Full Text
• [45]Li M, Abdollahi A, Grone HJ, Lipson KE, Belka C, Huber PE: Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. Radiat Oncol 2009, 4:66. BioMed Central Full Text
• [46]Zerp SF, Stoter R, Kuipers G, Yang D, Lippman ME, van Blitterswijk WJ, Bartelink H, Rooswinkel R, Lafleur V, Verheij M: AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis. Radiat Oncol 2009, 4:47. BioMed Central Full Text
• [47]Scorsetti M, Navarria P, Mancosu P, Alongi F, Castiglioni S, Cavina R, Cozzi L, Fogliata A, Pentimalli S, Tozzi A, et al.: Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arc. Radiat Oncol 2010, 5:94. BioMed Central Full Text
• [48]Huang TC, Liang JA, Dilling T, Wu TH, Zhang G: Four-dimensional dosimetry validation and study in lung radiotherapy using deformable image registration and Monte Carlo techniques. Radiat Oncol 2010, 5:45. BioMed Central Full Text
• [49]Shi A, Zhu G, Wu H, Yu R, Li F, Xu B: Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy. Radiat Oncol 2010, 5:35. BioMed Central Full Text
• [50]Yamashita H, Kobayashi-Shibata S, Terahara A, Okuma K, Haga A, Wakui R, Ohtomo K, Nakagawa K: Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol 2010, 5:32. BioMed Central Full Text